Intuitive Surgical (ISRG) Investors – Latest Update

By Ken Smith • Friday, June 13 10:04 • Permanent Link

We're taking a closer look at Intuitive Surgical today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 0.0% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
Intuitive Surgical has moved 20.5% over the last year compared to 11.3% for the S&P 500 -- a difference of 9.2%
ISRG has an average analyst rating of buy and is -10.82% away from its mean target price of $575.49 per share
Its trailing 12 month earnings per share (EPS) is $6.82
Intuitive Surgical has a trailing 12 month Price to Earnings (P/E) ratio of 75.3 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $7.86 and its forward P/E ratio is 65.3
The company has a Price to Book (P/B) ratio of 10.75 in contrast to the S&P 500's average ratio of 4.74
Intuitive Surgical is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
Intuitive Surgical has on average reported free cash flows of $1.18 Billion over the last four years, during which time they have grown by an an average of 2.4%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.